Syndax (Nasdaq: SNDX) announced that Chief Executive Officer Michael A. Metzger will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. A live webcast will be available in the company's Investor section at www.syndax.com, and a replay will be accessible for a limited time.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction
-5.07%
21 alerts
-5.07%News Effect
-2.9%Trough in 1 hr 51 min
-$94MValuation Impact
$1.76BMarket Cap
0.4xRel. Volume
On the day this news was published, SNDX declined 5.07%, reflecting a notable negative market reaction.
Argus tracked a trough of -2.9% from its starting point during tracking.
Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
This price movement removed approximately $94M from the company's valuation, bringing the market cap to $1.76B at that time.
Peers showed mixed moves: ARDX +5.31%, BHVN -4.66%, VERA -4.19%, VRDN -0.39%, TRML 0.00%, suggesting the SNDX setup is more stock-specific than a sector-wide move.
Inducement equity awards granting options to four new employees.
Pattern Detected
Recent positive clinical and award news often coincided with mild negative price reactions, while neutral items like conferences and inducement grants showed modest, mixed moves.
Recent Company History
Over the last two months, Syndax has highlighted growing momentum around Revuforj, including strong ASH 2025 data and the drug being named Best New Drug at the Scrip Awards 2025. Neutral items such as conference appearances and inducement grants have been frequent, with modest share price moves. Regulatory filings showed FDA approval of Revuforj for NPM1-mutated AML on October 24, 2025 and detailed Q3 2025 revenue and cash levels. Today’s J.P. Morgan conference presentation fits into this pattern of ongoing visibility and investor outreach rather than a new clinical or regulatory catalyst.
Market Pulse Summary
The stock moved -5.1% in the session following this news. A negative reaction despite this routine c...
Analysis
The stock moved -5.1% in the session following this news. A negative reaction despite this routine conference announcement would fit a pattern where even positive catalysts, such as strong ASH data or awards, previously coincided with weak price follow-through. The stock had been trading above its 200-day MA and well off its 52-week low ahead of the news, leaving room for profit-taking. Any sharp decline might also prompt focus back on fundamentals like continuing net losses and significant royalty obligations related to Niktimvo.
"for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation"
A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.
npm1 mutationmedical
"relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in adult and pediatric patients"
A NPM1 mutation is a specific change in the NPM1 gene that alters a protein involved in controlling cell growth and location inside cells; it is most commonly seen in a subtype of acute myeloid leukemia (AML). Investors care because it serves as a clear biomarker used to diagnose and monitor the disease, predict how aggressive it will be, and identify patients who may benefit from targeted drugs or tests—much like a factory's wrong instruction sheet that both reveals a problem and points to a precise fix.
menin inhibitormedical
"Revuforj is a first-in-class menin inhibitor that received FDA approval in November 2024"
A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.
kmt2a translocationmedical
"for relapsed or refractory acute leukemia with a KMT2A translocation in patients one year and older"
A KMT2A translocation is a genetic rearrangement where the KMT2A gene is cut and joined to another gene, similar to two pages from different instruction manuals getting stapled together. It is most often seen in certain aggressive blood cancers and can change how cells behave, affect a patient’s outlook, and determine which treatments might work. For investors, it signals a specific medical need, a clear diagnostic marker, and a target for drugs or tests that can drive research priorities, regulatory review, and commercial opportunity.
nccn guidelinesmedical
"Revuforj was added to the NCCN Guidelines for AML on September 18, 2025."
NCCN Guidelines are evidence-based recommendations for cancer diagnosis, treatment and care developed by a network of cancer specialists; think of them as an expert-approved roadmap clinicians use to choose therapies. They matter to investors because inclusion or alignment with these guidelines can speed clinical adoption, influence insurance coverage and reimbursement, and signal clinical credibility — all of which affect a treatment’s commercial potential and a company’s market value.
rule 10b5-1 planregulatory
"and then sold the same 157,307 shares under a Rule 10b5-1 plan at prices ranging"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
schedule 13gregulatory
"SCHEDULE 13G] Syndax Pharmaceuticals, Inc. SEC Filing"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
form 144regulatory
"Form 144 notice for SNDX reports a proposed sale of 43,200 shares of common stock"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.
A live webcast of the presentation will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (SNDX) present at the 44th Annual J.P. Morgan Healthcare Conference?
Syndax will present on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET.
Who will present for Syndax (SNDX) at the January 2026 J.P. Morgan Healthcare Conference?
Chief Executive Officer Michael A. Metzger will deliver the presentation.
How can investors watch Syndax (SNDX) presentation on January 12, 2026?
A live webcast will be available in the Investor section of www.syndax.com, with a limited-time replay.
Will there be a replay of the Syndax (SNDX) J.P. Morgan presentation?
Yes, a replay will be available on the company's investor website for a limited time after the live webcast.
What time is the Syndax (SNDX) webcast for international viewers on January 12, 2026?
The presentation is at 6:00 p.m. ET, which is 3:00 p.m. PT; viewers should convert to their local time zone.
